Guidelines & Consensus
Receptor Conversion After Neoadjuvant Breast Cancer Therapy
Pogoda et alJournal of Clinical Medicine
Receptor conversion following neoadjuvant therapy in breast cancer can substantially alter eligibility for adjuvant systemic regimens, yet clinical practice guidelines offer limited guidance on biomarker-guided treatment adaptation. To address this uncertainty, a nationwide cross-sectional survey evaluated treatment adaptation and decision-making among 104 Polish medical oncologists managing breast cancer across five specific receptor conversion scenarios.
Treatment approaches were classified into a three-strategy framework: baseline-driven (relying strictly on pretreatment biomarkers), residual disease-driven (relying solely on residual disease biomarkers), and combined (integrating both pretreatment and residual biomarkers). Routine reassessment of receptor status in residual disease was reported by 52.9% of oncologists, and 73.1% incorporated residual disease biomarkers into adjuvant treatment decisions either routinely or selectively. Across all clinical scenarios, baseline-driven strategies accounted for only 26.3% of decisions, whereas combined strategies (40.2%) and residual disease-driven strategies (33.5%) comprised the majority of therapeutic choices.
Treatment decisions varied markedly by conversion subtype. Combined approaches were preferred following hormone receptor conversion, utilized by 52.9% of respondents for shifts from luminal HER2-negative to triple-negative breast cancer (TNBC) and 55.8% for shifts from TNBC to luminal HER2-negative disease. In cases of HER2 loss, oncologists most frequently maintained baseline-driven approaches (42.3%). Conversely, when tumors acquired HER2 positivity, clinicians favored residual disease-driven strategies for TNBC-to-HER2-positive conversion (46.2%) and combined strategies for luminal HER2-negative-to-HER2-positive conversion (48.1%). These findings illustrate that most oncologists actively incorporate residual disease biology into systemic treatment planning despite guideline gaps, establishing a practical framework to guide future clinical trials on biomarker-directed adjuvant therapy.
Key Takeaways
- In a survey of 104 medical oncologists, 73.1% incorporated residual disease biomarkers into post-neoadjuvant treatment planning either routinely or selectively, with baseline-only strategies accounting for just 26.3% of therapeutic decisions compared to combined (40.2%) and residual disease-driven (33.5%) strategies.
- Combined therapeutic strategies predominated following hormone receptor conversion, selected by 52.9% of oncologists for luminal HER2-negative-to-TNBC shifts and 55.8% for TNBC-to-luminal HER2-negative shifts.
- Following HER2 loss, baseline-driven strategies were most frequently chosen (42.3%), whereas HER2 gain prompted residual disease-driven management in TNBC-to-HER2-positive conversion (46.2%) and combined strategies in luminal HER2-negative-to-HER2-positive conversion (48.1%).
Read the original sourceJournal of Clinical Medicine
